Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Alignment Healthcare, Inc. (ALHC) · oqro.io/stocks/ALHC · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Questions about Alignment Healthcare, Inc. insider trading
Have Alignment Healthcare, Inc. insiders bought shares recently?
No open-market purchase by an insider of Alignment Healthcare, Inc. was filed in the last 90 days. The latest on record was on Jun 3, 2026.
How often do Alignment Healthcare, Inc. insiders buy and sell shares?
Since 2021, Alignment Healthcare, Inc. insiders reported 3 open-market purchases and 399 sales on Forms 4 and 5, with purchases in 3 different years, most recently 2026.
Who is selling Alignment Healthcare, Inc. stock?
In the last 90 days, 4 insiders of Alignment Healthcare, Inc. (ALHC) reported 7 open-market sales worth $9.54M in total on SEC Form 4. The largest seller by value was John E Kao, with $7.48M. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Do members of Congress trade ALHC?
No trade in Alignment Healthcare, Inc. (ALHC) was disclosed by a member of Congress in the last 12 months.
When does Alignment Healthcare, Inc. report its next results?
Alignment Healthcare, Inc.'s next results are expected on Feb 24, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−60.4% (−$9.70) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $16.07 on Nov 20, 2025 to $6.37 on Nov 20, 2026 (−60.4%). Disclosed in this range: 1 insider trade, 78 pre-arranged insider sales, 0 Congress trades, and 17 13F position changes for 3 quarters ending in it.
$0$10$15$20$25$30$6.37
DecJan 2026FebMarAprMayJunJulAugSepOctNov
13F holdings, by quarter end
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Fund 13F reports are quarter-end snapshots filed up to 45 days later, so they are shown under the chart across the quarter they describe, not on the price line. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.Show the 79 trades in this range as a list
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Health Care Services company based in Orange, California.
Last 12 months
−60.4%
S&P 500 +5.7% over the same dates
Market value
$1.56B
Close of Nov 20, 2026 × shares outstanding (per ADS where it applies)
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 23.1M shares sold short (9.4% of shares outstanding), −9.3% vs the previous count, 3.9 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Latest results: quarter ending Sep 30, 2026
Revenue
$1.36B
+36.7% vs the same quarter a year earlier
Free cash flow, last 12 months
$77M
This quarter $38.6M, a year earlier $139M
Net cash
$403M
Debt $324M, cash $728M, at Sep 30, 2026
Net income, last 12 months
$28.9M
Operating profit covers interest 2.63x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Oct 29, 2026.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insider buying and selling since 2021
Insiders of Alignment Healthcare, Inc. reported 3 open-market purchases and 399 sales since 2021; purchases in 3 different years, most recently 2026.
Year
Bought
Sold
2026
$198K1×1 trade
$79.1M60×60 trades
2025
—
$1.67B129×129 trades
2024
$496K1×1 trade
$17.7M81×81 trades
2023
$662K1×1 trade
$1.45M23×23 trades
2022
—
$448M73×73 trades
2021
—
$629M33×33 trades
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Last 30 days
Written by software from the filings listed below · Oct 11, 2026
Insiders. In the 30 days to Oct 11, 2026, insiders of Alignment Healthcare, Inc. filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 6 open-market sales (about $9.51M, in 5 filings, by 4 people). One Form 4 can list many transactions. In the 30 days before that, they filed 0 open-market purchases (about $0, in 0 filings) and 1 open-market sale (about $70K, in 1 filing). (Alignment Healthcare, Inc. on OQRO)
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. This describes public filings. It is not investment advice.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 30 days to Oct 11, 2026, insiders of Alignment Healthcare, Inc. filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 6 open-market sales (about $9.51M, in 5 filings, by 4 people). One Form 4 can list many transactions.
In the 30 days before that, they filed 0 open-market purchases (about $0, in 0 filings) and 1 open-market sale (about $70K, in 1 filing).
The largest sale: John E Kao, Chief Executive Officer, about $4.89M, filed Sep 12, 2026.
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
This describes public filings. It is not investment advice.
6 certified in FY2026 Q3, vs 0 a year earlier. 6 positions in total, median offered wage $142K a year.
Data Analyst · 1Principal Project Manager · 1Senior Data Engineer · 1Sr. Data Engineer · 1Sr. Manager, Quality Assurance · 1
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
The year in the managers' words
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 9,000 words.
From “Overview”, in the company's words
Alignment is a next generation, consumer-centric and clinically focused platform designed to improve the healthcare experience for seniors. We deliver this experience through our Medicare Advantage plans, which are customized to meet the needs of a diverse array of seniors. Our innovative model of consumer-centric healthcare is purpose-built to provide seniors with care as it should be: high quality, low cost and accompanied by a vastly improved consumer experience. We combine a proprietary technology platform and a high-touch clinical model that enhances our members’ lifestyles and health outcomes while simultaneously controlling costs, which allows us to reinvest savings back into our platform and products to directly benefit the senior consumers.
What the section covers (24 headings)
Overview
Factors Affecting Our Performance
Key Business Metrics
Health Plan Membership
Adjusted Gross Profit and Medical Benefits Ratio
Adjusted EBITDA
Results of Operations
Revenues
Expenses
Other Expense
Other Expenses
Liquidity and Capital Resources
General
Oxford Term Loan
And 10 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Feb 27, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
When insiders usually buy
Last results
Oct 29, 2026
Within the 30 days after it, until Nov 28, 2026
Next results, expected
Feb 24, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
Not enough history
From Alignment Healthcare, Inc.'s own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Alignment Healthcare, Inc.'s policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Insiders. In the 12 months to Nov 19, 2026, insiders of Alignment Healthcare, Inc. filed 1 open-market purchase (about $198K, in 1 filing, by 1 person) and 78 open-market sales (about $518M, in 58 filings, by 11 people). One Form 4 can list many transactions. In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 116 open-market sales (about $1.23B, in 79 filings). (Alignment Healthcare, Inc. on OQRO)
Funds and stakes. Fund 13F filings recorded in the 12 months show 11 new or larger positions and 6 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter. FMR LLC cut its ALHC stake below 5% (4.3%) (filed Nov 5, 2026).
Contracts, lobbying and filings. FINRA short interest for ALHC on the settlement date of Oct 30, 2026 was 23,149,408 shares (-9.3% on the previous report), about 3.91 days of average volume. In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew: William Blair Investment Management, LLC (increased, 2,546,789 shares); Hood River Capital Management LLC (increased, 130,049 shares); the largest that shrank: Hillsdale Investment Management Inc. (sold out); OP Asset Management Ltd (sold out). A 13F is a quarter-end snapshot with no trade date.
Company reports, price and press. Alignment Healthcare, Inc. filed a Form 8-K on Oct 29, 2026 (Item 2.02) that OQRO classes as: reported its results. Alignment Healthcare, Inc. filed a Form 8-K on Jul 30, 2026 (Item 2.02) that OQRO classes as: reported its results.
Who holds it. 322 funds reported a stake in Alignment Healthcare, Inc. in their 13F for Q2 2026. The largest by value: BlackRock, Inc. (8.7% of the value reported), WELLINGTON MANAGEMENT GROUP LLP (8.4% of the value reported), FMR LLC (6.3% of the value reported).
Off-exchange trading: 46.8% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (22.6% on ATS, 24.2% with other brokers), close to its 26-week average of 45.2%. Weeks of Sep 21 to Oct 16, 2026.
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 12 months to Nov 19, 2026, insiders of Alignment Healthcare, Inc. filed 1 open-market purchase (about $198K, in 1 filing, by 1 person) and 78 open-market sales (about $518M, in 58 filings, by 11 people). One Form 4 can list many transactions.
In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 116 open-market sales (about $1.23B, in 79 filings).
The largest purchase: Mark D. Kent, President - MSO, about $198K, filed Jun 3, 2026.
The largest sale: GENERAL ATLANTIC, L.P., 10% owner, about $206M, filed Dec 13, 2025.
Funds and stakes
Fund 13F filings recorded in the 12 months show 11 new or larger positions and 6 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
FMR LLC cut its ALHC stake below 5% (4.3%) (filed Nov 5, 2026).
Contracts, lobbying and filings
FINRA short interest for ALHC on the settlement date of Oct 30, 2026 was 23,149,408 shares (-9.3% on the previous report), about 3.91 days of average volume.
In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew: William Blair Investment Management, LLC (increased, 2,546,789 shares); Hood River Capital Management LLC (increased, 130,049 shares); the largest that shrank: Hillsdale Investment Management Inc. (sold out); OP Asset Management Ltd (sold out). A 13F is a quarter-end snapshot with no trade date.
For fiscal 2025, the company's proxy statement reported total compensation of $11.3M for its principal executive officer, and an average of $3.57M for the other named executive officers.
Company reports, price and press
Alignment Healthcare, Inc. filed a Form 8-K on Oct 29, 2026 (Item 2.02) that OQRO classes as: reported its results.
Alignment Healthcare, Inc. filed a Form 8-K on Jul 30, 2026 (Item 2.02) that OQRO classes as: reported its results.
Alignment Healthcare, Inc. filed a Form 8-K on May 12, 2026 (Items 5.03, 7.01) that OQRO classes as: changed its bylaws, charter or fiscal year, and shared information with investors.
ALHC closed at $6.72 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $8.40 to $6.72, a change of −20.0%.
Who holds it
322 funds reported a stake in Alignment Healthcare, Inc. in their 13F for Q2 2026. The largest by value: BlackRock, Inc. (8.7% of the value reported), WELLINGTON MANAGEMENT GROUP LLP (8.4% of the value reported), FMR LLC (6.3% of the value reported).
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
An 8-K item says what the company reported, not what it means for the share price.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
Week of Apr 20ATSOther off-exchangeFull height = all shares tradedWeek of Oct 12
Largest ATS: INTELLIGENT CROSS LLC (10.1%), BIDS ATS (8.8%), UBS ATS (8.4%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Risk factors in the annual report
Latest annual report filed Feb 27, 2026, compared with the one filed Feb 27, 2025. Read the filing
New risk factors in the latest annual report (2 headings)
Our use of machine learning and artificial intelligence, including within our AVA platform, may introduce operational, regulatory and legal risks that could adversely affect our business, financial condition and results of operations.
The terms and conditions of our Revolving Credit Facility restrict our current and future operations, particularly our ability to respond to changes or to take certain actions.
No longer listed (6 headings from the year before)
Our relatively limited operating history makes it difficult to evaluate our current business and future prospects and increases the risk of your investment.
Our management team has limited experience managing a public company.
We have limited experience serving as a participant in the ACO REACH model with CMS and may not be able to realize the expected benefits thereof.
If we are unable to maintain the minimum required number of beneficiaries served by our ACO REACH model, we may become ineligible to participate in the program.
Our Lead Sponsor holds a substantial percentage of our outstanding common stock and has the ability to significantly influence our management, business plans and policies and the election of our directors, and their interests may conflict with ours or the holders of our common stock in the future.
Our business could be negatively impacted by environmental, social and corporate governance matters or our reporting of such matters.
Legal proceedings (Item 3)
We are from time to time subject to, and are presently involved in, litigation and other legal proceedings. We believe that there are no pending lawsuits or claims that, individually or in the aggregate, may have a material effect on our business, financial condition or operating results. The results of any future claims or proceedings cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of defense and litigation costs, diversion of management resources, and other factors.
The company describes its cases in the notes to its financial statements, in the same filing.
Source: SEC EDGAR, Form 10-K filed Feb 27, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Since Nov 19, 2025, ALHC is down 61.0% and the index fund is up 4.1%: 65 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much ALHC moves
A usual day
±1.9%Half of the sessions moved less than this, half moved more.
Daily range (ATR 14)
8.6%How far the price usually travels in a session, the gap from the day before included. Wilder's 14-session average.
Largest one-day fall
−20.2%Jul 31, 2026
Largest one-day rise
+25.1%Jun 9, 2026
Deepest fall of the year
−74.1%From the close of Jul 6, 2026 to Nov 20, 2026.
Days of 5% or more
35Out of 252 sessions, in either direction.
Beta 0.6(1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 251 trading days (1 = in step with it).